Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II controlled study of pegylated liposomal doxorubicin (Caelyx) plus carboplatin as neoadjuvant therapy in breast cancer
2007-004925-64Phase 2Terminated
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Mar 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pegylated liposomal doxorubicin and carboplatin in breast cancer, sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Overall response rate after 6 cycles. Started Mar 2008; status: terminated.
02
Drugs
pegylated liposomal doxorubicincarboplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-004925-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004925-64.